title: Multidisciplinary management of early-stage rectal cancer.
abstract: Because patients with locally advanced rectal cancer are at high risk for both recurrence and distant disease, they require adjuvant therapy. In the United States, the current standard of care is neoadjuvant chemoradiation followed by surgery and adjuvant chemotherapy. Neoadjuvant chemoradiation has been shown to improve local recurrence rates and decrease toxicity. However in the era of total mesorectal excision surgery, no study has shown a survival benefit to either chemoradiation or postoperative chemotherapy. Newer biologic therapies, although promising in initial early trials, have yet to show a significant benefit in adjuvant therapy for rectal cancer.
authors.affiliation: Harvard Radiation Oncology Program, Harvard Medical School, Boston, Massachusetts, USA.
authors.forename: John G
authors.initials: JG
authors.lastname: Phillips
authors.forename: Theodore S
authors.initials: TS
authors.lastname: Hong
authors.forename: David P
authors.initials: DP
authors.lastname: Ryan
mesh_terms: D003131:Combined Modality Therapy / Q000379:methods*; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000473:pathology / Q000628:therapy; D009367:Neoplasm Staging; D016032:Randomized Controlled Trials as Topic; D012004:Rectal Neoplasms / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D012007:Rectum / Q000473:pathology / Q000601:surgery